85%Confidence
0Views
FDASource
2026-03-30Date
Summary
Cipla's Nilotinib Capsules recall due to stability failures indicates potential quality control issues at their Goa facility, which could impact supply of this cancer medication and damage Cipla's reputation in regulated markets. This Class III recall suggests lower health risk but may trigger increased FDA scrutiny on Cipla's manufacturing processes.
Actionable: Monitor Cipla's stock for potential impact from manufacturing quality concerns and regulatory oversight.
AI Confidence: 85%
Data Points
firmCipla USA, Inc.
classificationClass III
statusOngoing
distributionU.S.A. Nationwide
productNilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now